The development of anticyclic citrullinated peptide (anti‐CCP) antibody following severe COVID‐19

Objectives The dysregulated immune response is one of the cardinal features of severe coronavirus disease 2019 (COVID‐19). This study was conducted to clarify the occurrence of autoantibodies (AABs) associated with systemic autoimmune rheumatic diseases (SARDs) in hospitalized patients with a modera...

Full description

Saved in:
Bibliographic Details
Published inImmunity, Inflammation and Disease Vol. 12; no. 5; pp. e1276 - n/a
Main Authors Roghani, Seyed Askar, Dastbaz, Mohammad, Lotfi, Ramin, Shamsi, Afsaneh, Abdan, Zahra, Rostampour, Rezvan, Soleymani, Bijan, Zamanian, Mohammad Hossein, Soufivand, Parviz, Pournazari, Mehran, Taghadosi, Mahdi
Format Journal Article
LanguageEnglish
Published England John Wiley & Sons, Inc 01.05.2024
John Wiley and Sons Inc
Wiley
Subjects
Adult
Aged
Anti-Citrullinated Protein Antibodies - blood
Anti-Citrullinated Protein Antibodies - immunology
Antibodies
Antibodies, Antinuclear - blood
Antibodies, Antinuclear - immunology
anti‐CCP
autoantibodies (AABs)
Autoantibodies - blood
Autoantibodies - immunology
Autoimmune diseases
Autoimmune Diseases - blood
Autoimmune Diseases - immunology
autoimmunity
Coronaviruses
Correlation analysis
COVID-19
COVID-19 - blood
COVID-19 - immunology
Female
Humans
Immunoglobulins
Lupus
Male
Middle Aged
Neutrophils
Original
Patients
Peptides
Rheumatic diseases
Rheumatic Diseases - blood
Rheumatic Diseases - immunology
Rheumatoid arthritis
SARS-CoV-2 - immunology
SARS‐CoV‐2
Sea level
Severity of Illness Index
Iran
autoantibodies (AABs)
COVID‐19
autoimmunity
SARS‐CoV‐2
anti‐CCP
Online AccessGet full text

Cover

Abstract Objectives The dysregulated immune response is one of the cardinal features of severe coronavirus disease 2019 (COVID‐19). This study was conducted to clarify the occurrence of autoantibodies (AABs) associated with systemic autoimmune rheumatic diseases (SARDs) in hospitalized patients with a moderate, severe, and critical form of COVID‐19. Methods The serum samples obtained from 176 hospitalized COVID‐19 patients were investigated in this study, including patients with moderate (N = 90), severe (N = 50), and critical (N = 36) forms of COVID‐19. Also, the serum samples collected from healthy subjects before the COVID‐19 pandemic were used as controls (N = 176). The antinuclear antibodies (ANAs), antidouble‐stranded DNA (anti‐dsDNA), cytoplasmic‐anti neutrophil cytoplasmic antibody (c‐ANCA), perinuclear ANCA (p‐ANCA), antiphospholipid antibodies (aPLs), and anticyclic citrullinated peptide (anti‐CCP) occurrence was evaluated using a solid‐phase enzyme‐linked immunosorbent assay (ELISA). Results The results showed that the occurrence of ANAs, anti‐dsDNA, anti‐CCP, c‐ANCA, and p‐ANCA was significantly higher in the COVID‐19 patients compared to serum obtained from healthy subjects (p < .0001, p < .0001, p < .0001, p < .05, and p < .001, respectively). The positive number of anti‐CCP tests increased significantly in severe COVID‐19 compared to the moderate group (p < .01). Conclusion Our study further supports the development of autoantibodies related to systemic autoimmune rheumatologic diseases. To the best of our knowledge, this is the first study with a large sample size that reported the occurrence of anti‐CCP in a severe form of COVID‐19.
AbstractList The dysregulated immune response is one of the cardinal features of severe coronavirus disease 2019 (COVID-19). This study was conducted to clarify the occurrence of autoantibodies (AABs) associated with systemic autoimmune rheumatic diseases (SARDs) in hospitalized patients with a moderate, severe, and critical form of COVID-19. The serum samples obtained from 176 hospitalized COVID-19 patients were investigated in this study, including patients with moderate (N = 90), severe (N = 50), and critical (N = 36) forms of COVID-19. Also, the serum samples collected from healthy subjects before the COVID-19 pandemic were used as controls (N = 176). The antinuclear antibodies (ANAs), antidouble-stranded DNA (anti-dsDNA), cytoplasmic-anti neutrophil cytoplasmic antibody (c-ANCA), perinuclear ANCA (p-ANCA), antiphospholipid antibodies (aPLs), and anticyclic citrullinated peptide (anti-CCP) occurrence was evaluated using a solid-phase enzyme-linked immunosorbent assay (ELISA). The results showed that the occurrence of ANAs, anti-dsDNA, anti-CCP, c-ANCA, and p-ANCA was significantly higher in the COVID-19 patients compared to serum obtained from healthy subjects (p < .0001, p < .0001, p < .0001, p < .05, and p < .001, respectively). The positive number of anti-CCP tests increased significantly in severe COVID-19 compared to the moderate group (p < .01). Our study further supports the development of autoantibodies related to systemic autoimmune rheumatologic diseases. To the best of our knowledge, this is the first study with a large sample size that reported the occurrence of anti-CCP in a severe form of COVID-19.
ObjectivesThe dysregulated immune response is one of the cardinal features of severe coronavirus disease 2019 (COVID-19). This study was conducted to clarify the occurrence of autoantibodies (AABs) associated with systemic autoimmune rheumatic diseases (SARDs) in hospitalized patients with a moderate, severe, and critical form of COVID-19.MethodsThe serum samples obtained from 176 hospitalized COVID-19 patients were investigated in this study, including patients with moderate (N = 90), severe (N = 50), and critical (N = 36) forms of COVID-19. Also, the serum samples collected from healthy subjects before the COVID-19 pandemic were used as controls (N = 176). The antinuclear antibodies (ANAs), antidouble-stranded DNA (anti-dsDNA), cytoplasmic-anti neutrophil cytoplasmic antibody (c-ANCA), perinuclear ANCA (p-ANCA), antiphospholipid antibodies (aPLs), and anticyclic citrullinated peptide (anti-CCP) occurrence was evaluated using a solid-phase enzyme-linked immunosorbent assay (ELISA).ResultsThe results showed that the occurrence of ANAs, anti-dsDNA, anti-CCP, c-ANCA, and p-ANCA was significantly higher in the COVID-19 patients compared to serum obtained from healthy subjects (p < .0001, p < .0001, p < .0001, p < .05, and p < .001, respectively). The positive number of anti-CCP tests increased significantly in severe COVID-19 compared to the moderate group (p < .01).ConclusionOur study further supports the development of autoantibodies related to systemic autoimmune rheumatologic diseases. To the best of our knowledge, this is the first study with a large sample size that reported the occurrence of anti-CCP in a severe form of COVID-19.
Abstract Objectives The dysregulated immune response is one of the cardinal features of severe coronavirus disease 2019 (COVID‐19). This study was conducted to clarify the occurrence of autoantibodies (AABs) associated with systemic autoimmune rheumatic diseases (SARDs) in hospitalized patients with a moderate, severe, and critical form of COVID‐19. Methods The serum samples obtained from 176 hospitalized COVID‐19 patients were investigated in this study, including patients with moderate (N = 90), severe (N = 50), and critical (N = 36) forms of COVID‐19. Also, the serum samples collected from healthy subjects before the COVID‐19 pandemic were used as controls (N = 176). The antinuclear antibodies (ANAs), antidouble‐stranded DNA (anti‐dsDNA), cytoplasmic‐anti neutrophil cytoplasmic antibody (c‐ANCA), perinuclear ANCA (p‐ANCA), antiphospholipid antibodies (aPLs), and anticyclic citrullinated peptide (anti‐CCP) occurrence was evaluated using a solid‐phase enzyme‐linked immunosorbent assay (ELISA). Results The results showed that the occurrence of ANAs, anti‐dsDNA, anti‐CCP, c‐ANCA, and p‐ANCA was significantly higher in the COVID‐19 patients compared to serum obtained from healthy subjects (p < .0001, p < .0001, p < .0001, p < .05, and p < .001, respectively). The positive number of anti‐CCP tests increased significantly in severe COVID‐19 compared to the moderate group (p < .01). Conclusion Our study further supports the development of autoantibodies related to systemic autoimmune rheumatologic diseases. To the best of our knowledge, this is the first study with a large sample size that reported the occurrence of anti‐CCP in a severe form of COVID‐19.
Abstract Objectives The dysregulated immune response is one of the cardinal features of severe coronavirus disease 2019 (COVID‐19). This study was conducted to clarify the occurrence of autoantibodies (AABs) associated with systemic autoimmune rheumatic diseases (SARDs) in hospitalized patients with a moderate, severe, and critical form of COVID‐19. Methods The serum samples obtained from 176 hospitalized COVID‐19 patients were investigated in this study, including patients with moderate ( N  = 90), severe ( N  = 50), and critical ( N  = 36) forms of COVID‐19. Also, the serum samples collected from healthy subjects before the COVID‐19 pandemic were used as controls ( N  = 176). The antinuclear antibodies (ANAs), antidouble‐stranded DNA (anti‐dsDNA), cytoplasmic‐anti neutrophil cytoplasmic antibody (c‐ANCA), perinuclear ANCA (p‐ANCA), antiphospholipid antibodies (aPLs), and anticyclic citrullinated peptide (anti‐CCP) occurrence was evaluated using a solid‐phase enzyme‐linked immunosorbent assay (ELISA). Results The results showed that the occurrence of ANAs, anti‐dsDNA, anti‐CCP, c‐ANCA, and p‐ANCA was significantly higher in the COVID‐19 patients compared to serum obtained from healthy subjects ( p  < .0001, p  < .0001, p  < .0001, p  < .05, and p  < .001, respectively). The positive number of anti‐CCP tests increased significantly in severe COVID‐19 compared to the moderate group ( p  < .01). Conclusion Our study further supports the development of autoantibodies related to systemic autoimmune rheumatologic diseases. To the best of our knowledge, this is the first study with a large sample size that reported the occurrence of anti‐CCP in a severe form of COVID‐19.
Objectives The dysregulated immune response is one of the cardinal features of severe coronavirus disease 2019 (COVID‐19). This study was conducted to clarify the occurrence of autoantibodies (AABs) associated with systemic autoimmune rheumatic diseases (SARDs) in hospitalized patients with a moderate, severe, and critical form of COVID‐19. Methods The serum samples obtained from 176 hospitalized COVID‐19 patients were investigated in this study, including patients with moderate (N = 90), severe (N = 50), and critical (N = 36) forms of COVID‐19. Also, the serum samples collected from healthy subjects before the COVID‐19 pandemic were used as controls (N = 176). The antinuclear antibodies (ANAs), antidouble‐stranded DNA (anti‐dsDNA), cytoplasmic‐anti neutrophil cytoplasmic antibody (c‐ANCA), perinuclear ANCA (p‐ANCA), antiphospholipid antibodies (aPLs), and anticyclic citrullinated peptide (anti‐CCP) occurrence was evaluated using a solid‐phase enzyme‐linked immunosorbent assay (ELISA). Results The results showed that the occurrence of ANAs, anti‐dsDNA, anti‐CCP, c‐ANCA, and p‐ANCA was significantly higher in the COVID‐19 patients compared to serum obtained from healthy subjects (p < .0001, p < .0001, p < .0001, p < .05, and p < .001, respectively). The positive number of anti‐CCP tests increased significantly in severe COVID‐19 compared to the moderate group (p < .01). Conclusion Our study further supports the development of autoantibodies related to systemic autoimmune rheumatologic diseases. To the best of our knowledge, this is the first study with a large sample size that reported the occurrence of anti‐CCP in a severe form of COVID‐19.
The dysregulated immune response is one of the cardinal features of severe coronavirus disease 2019 (COVID-19). This study was conducted to clarify the occurrence of autoantibodies (AABs) associated with systemic autoimmune rheumatic diseases (SARDs) in hospitalized patients with a moderate, severe, and critical form of COVID-19.OBJECTIVESThe dysregulated immune response is one of the cardinal features of severe coronavirus disease 2019 (COVID-19). This study was conducted to clarify the occurrence of autoantibodies (AABs) associated with systemic autoimmune rheumatic diseases (SARDs) in hospitalized patients with a moderate, severe, and critical form of COVID-19.The serum samples obtained from 176 hospitalized COVID-19 patients were investigated in this study, including patients with moderate (N = 90), severe (N = 50), and critical (N = 36) forms of COVID-19. Also, the serum samples collected from healthy subjects before the COVID-19 pandemic were used as controls (N = 176). The antinuclear antibodies (ANAs), antidouble-stranded DNA (anti-dsDNA), cytoplasmic-anti neutrophil cytoplasmic antibody (c-ANCA), perinuclear ANCA (p-ANCA), antiphospholipid antibodies (aPLs), and anticyclic citrullinated peptide (anti-CCP) occurrence was evaluated using a solid-phase enzyme-linked immunosorbent assay (ELISA).METHODSThe serum samples obtained from 176 hospitalized COVID-19 patients were investigated in this study, including patients with moderate (N = 90), severe (N = 50), and critical (N = 36) forms of COVID-19. Also, the serum samples collected from healthy subjects before the COVID-19 pandemic were used as controls (N = 176). The antinuclear antibodies (ANAs), antidouble-stranded DNA (anti-dsDNA), cytoplasmic-anti neutrophil cytoplasmic antibody (c-ANCA), perinuclear ANCA (p-ANCA), antiphospholipid antibodies (aPLs), and anticyclic citrullinated peptide (anti-CCP) occurrence was evaluated using a solid-phase enzyme-linked immunosorbent assay (ELISA).The results showed that the occurrence of ANAs, anti-dsDNA, anti-CCP, c-ANCA, and p-ANCA was significantly higher in the COVID-19 patients compared to serum obtained from healthy subjects (p < .0001, p < .0001, p < .0001, p < .05, and p < .001, respectively). The positive number of anti-CCP tests increased significantly in severe COVID-19 compared to the moderate group (p < .01).RESULTSThe results showed that the occurrence of ANAs, anti-dsDNA, anti-CCP, c-ANCA, and p-ANCA was significantly higher in the COVID-19 patients compared to serum obtained from healthy subjects (p < .0001, p < .0001, p < .0001, p < .05, and p < .001, respectively). The positive number of anti-CCP tests increased significantly in severe COVID-19 compared to the moderate group (p < .01).Our study further supports the development of autoantibodies related to systemic autoimmune rheumatologic diseases. To the best of our knowledge, this is the first study with a large sample size that reported the occurrence of anti-CCP in a severe form of COVID-19.CONCLUSIONOur study further supports the development of autoantibodies related to systemic autoimmune rheumatologic diseases. To the best of our knowledge, this is the first study with a large sample size that reported the occurrence of anti-CCP in a severe form of COVID-19.
Author Roghani, Seyed Askar
Rostampour, Rezvan
Shamsi, Afsaneh
Soufivand, Parviz
Taghadosi, Mahdi
Soleymani, Bijan
Pournazari, Mehran
Lotfi, Ramin
Dastbaz, Mohammad
Abdan, Zahra
Zamanian, Mohammad Hossein
AuthorAffiliation 2 Clinical Research Development Center, Imam Reza Hospital Kermanshah University of Medical Sciences Kermanshah Iran
6 Department of Clinical Biochemistry, Medical School Kermanshah University of Medical Sciences Kermanshah Iran
3 Medical Biology Research Center, Health Technology Institute Kermanshah University of Medical Sciences Kermanshah Iran
4 Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine Kurdistan Regional Blood Transfusion Center Sanandaj Iran
5 Clinical Research Development Center, Tohid Hospital Kurdistan University of Medical Sciences Sanandaj Iran
1 Immunology Department, Faculty of Medicine Kermanshah University of Medical Sciences Kermanshah Iran
AuthorAffiliation_xml – name: 4 Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine Kurdistan Regional Blood Transfusion Center Sanandaj Iran
– name: 5 Clinical Research Development Center, Tohid Hospital Kurdistan University of Medical Sciences Sanandaj Iran
– name: 6 Department of Clinical Biochemistry, Medical School Kermanshah University of Medical Sciences Kermanshah Iran
– name: 3 Medical Biology Research Center, Health Technology Institute Kermanshah University of Medical Sciences Kermanshah Iran
– name: 2 Clinical Research Development Center, Imam Reza Hospital Kermanshah University of Medical Sciences Kermanshah Iran
– name: 1 Immunology Department, Faculty of Medicine Kermanshah University of Medical Sciences Kermanshah Iran
Author_xml – sequence: 1
  givenname: Seyed Askar
  surname: Roghani
  fullname: Roghani, Seyed Askar
  organization: Kermanshah University of Medical Sciences
– sequence: 2
  givenname: Mohammad
  surname: Dastbaz
  fullname: Dastbaz, Mohammad
  organization: Kermanshah University of Medical Sciences
– sequence: 3
  givenname: Ramin
  orcidid: 0000-0002-5421-5280
  surname: Lotfi
  fullname: Lotfi, Ramin
  organization: Kurdistan University of Medical Sciences
– sequence: 4
  givenname: Afsaneh
  surname: Shamsi
  fullname: Shamsi, Afsaneh
  organization: Kermanshah University of Medical Sciences
– sequence: 5
  givenname: Zahra
  surname: Abdan
  fullname: Abdan, Zahra
  organization: Kermanshah University of Medical Sciences
– sequence: 6
  givenname: Rezvan
  surname: Rostampour
  fullname: Rostampour, Rezvan
  organization: Kermanshah University of Medical Sciences
– sequence: 7
  givenname: Bijan
  surname: Soleymani
  fullname: Soleymani, Bijan
  organization: Kermanshah University of Medical Sciences
– sequence: 8
  givenname: Mohammad Hossein
  surname: Zamanian
  fullname: Zamanian, Mohammad Hossein
  organization: Kermanshah University of Medical Sciences
– sequence: 9
  givenname: Parviz
  surname: Soufivand
  fullname: Soufivand, Parviz
  organization: Kermanshah University of Medical Sciences
– sequence: 10
  givenname: Mehran
  surname: Pournazari
  fullname: Pournazari, Mehran
  organization: Kermanshah University of Medical Sciences
– sequence: 11
  givenname: Mahdi
  orcidid: 0000-0002-3516-0130
  surname: Taghadosi
  fullname: Taghadosi, Mahdi
  email: mtaghad@gmail.com
  organization: Kermanshah University of Medical Sciences
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38780036$$D View this record in MEDLINE/PubMed
BookMark eNp1kstO3DAUhq2KqlDKoi9QReoGFgOOr8mqQqGXSEh0Qbu1bOdk8MgTp04Cml0foc_Ik-DMUASV6o0t-9Pn4-P_LdrrQgcIvc_xaY4xOXOuoac5keIVOiCY4wXjRO49W--jo2FYYYxzTCXFxRu0TwtZYEzFAYLrG8gauAUf-jV0YxbaTHejsxvrnc2sG-Pkvev0CE3WQz-6BrLjmbj__aeqvp9saROaTdYG78Od65bZkHwRsurqZ32RsLx8h1632g9w9Dgfoh9fPl9X3xaXV1_r6vxyYZnEYkGJ4SUjREiRCxDGEG6pFUaUheaSMc1ZQagBa4WljFsGwmIuLSuZtJQ09BDVO28T9Er10a113KigndpuhLhUOqbHeVCkZIyBNq0mJl0OJicaOAfZAC05xcn1aefqJ7OGxqbmRO1fSF-edO5GLcOtytMggshkOH40xPBrgmFUazdY8F53EKZBUcxLwiVmPKEf_0FXYYpd6lWixCwkskzUyY6yMQxDhPapmhyrOQxqDoOaw5DYD8_LfyL_fn0CznbAnfOw-b9J1fUF3SofAONVwAk
Cites_doi 10.1038/s41586-022-05273-0
10.1186/s13075-020-2121-6
10.1016/j.jtauto.2021.100091
10.1002/rmv.2316
10.1002/art.41425
10.1016/j.mehy.2008.12.040
10.1016/j.jaut.2023.103132
10.1111/cts.12805
10.26508/lsa.202101180
10.1007/s10067-023-06670-0
10.1002/rmv.2412
10.1016/j.jaut.2021.102682
10.1186/s12931-023-02650-9
10.1126/scitranslmed.abd3876
10.1586/1744666X.3.5.721
10.1136/annrheumdis-2021-219859
10.1002/art.20018
10.1007/s00296-021-04914-3
10.3389/fmed.2023.1201425
10.1038/s41586-021-03631-y
10.1136/annrheumdis-2015-208356
10.1016/j.cell.2022.01.014
10.1016/S0140-6736(20)30183-5
10.1038/s41572-020-0204-y
10.3389/fimmu.2018.00609
10.1016/j.intimp.2021.107806
10.1002/art.34380
10.1038/s41467-021-25509-3
10.1016/j.jaut.2019.06.006
10.3904/kjim.2013.28.1.25
10.1016/j.eclinm.2022.101783
10.1016/j.isci.2024.109573
10.1001/jama.2023.0157
10.1016/j.celrep.2020.108590
10.1136/ard.2005.041079
10.1002/art.40066
10.1172/JCI154886
10.1186/s13075-018-1752-3
10.3390/cells11182901
10.1016/j.ejr.2021.08.013
10.1056/NEJMoa2002032
10.1016/j.jtha.2023.02.033
ContentType Journal Article
Copyright 2024 The Authors. published by John Wiley & Sons Ltd.
2024 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.
2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2024 The Authors. published by John Wiley & Sons Ltd.
– notice: 2024 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.
– notice: 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
WIN
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
COVID
DWQXO
FYUFA
GHDGH
K9.
M0S
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1002/iid3.1276
DatabaseName Open Access: Wiley-Blackwell Open Access Journals
Wiley Online Library Free Content
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
Coronavirus Research Database
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Publicly Available Content Database
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
Coronavirus Research Database
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE
Publicly Available Content Database

CrossRef

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: 7X7
  name: Health & Medical Collection
  url: https://search.proquest.com/healthcomplete
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
DocumentTitleAlternate ROGHANI et al
EISSN 2050-4527
EndPage n/a
ExternalDocumentID oai_doaj_org_article_29444eabfa2b470eb12ae55e7de39530
10_1002_iid3_1276
38780036
IID31276
Genre article
Journal Article
GeographicLocations Iran
GeographicLocations_xml – name: Iran
GrantInformation_xml – fundername: Deputy of Research and Technology of the Kermanshah University of Medical Sciences
  funderid: 4000648
– fundername: Deputy of Research and Technology of the Kermanshah University of Medical Sciences (KUMS)
  funderid: 4000648
– fundername: Deputy for Research and Technology, Kermanshah University of Medical Sciences
  funderid: 4000648
– fundername: Deputy of Research and Technology of the Kermanshah University of Medical Sciences (KUMS)
  grantid: 4000648
– fundername: Deputy for Research and Technology, Kermanshah University of Medical Sciences
  grantid: 4000648
– fundername: Deputy of Research and Technology of the Kermanshah University of Medical Sciences
  grantid: 4000648
GroupedDBID 0R~
1OC
24P
53G
5VS
7X7
8-1
8FI
8FJ
AAHHS
AAZKR
ABDBF
ABUWG
ACCFJ
ACXQS
ADBBV
ADKYN
ADRAZ
ADZMN
ADZOD
AEEZP
AEQDE
AFKRA
AIWBW
AJBDE
ALAGY
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AOIJS
AVUZU
BAWUL
BCNDV
BENPR
BPHCQ
BVXVI
CCPQU
DIK
EBS
EJD
ESX
FYUFA
GODZA
GROUPED_DOAJ
HMCUK
HYE
IAO
IHR
INH
KQ8
M48
M~E
O9-
OK1
OVD
PIMPY
PQQKQ
PROAC
RPM
TEORI
UKHRP
WIN
CGR
CUY
CVF
ECM
EIF
ITC
NPM
AAYXX
CITATION
3V.
7XB
8FK
AZQEC
COVID
DWQXO
K9.
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c4706-32b5942267616e6bb25c3c6b698a5744a54823becc6c345c4e6c057c4947c32d3
IEDL.DBID RPM
ISSN 2050-4527
IngestDate Tue Oct 22 15:11:33 EDT 2024
Tue Sep 17 21:28:29 EDT 2024
Tue Aug 06 16:33:04 EDT 2024
Thu Oct 10 19:12:26 EDT 2024
Thu Sep 26 16:52:15 EDT 2024
Wed Oct 23 10:06:20 EDT 2024
Sat Aug 24 00:58:56 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords autoantibodies (AABs)
COVID‐19
autoimmunity
SARS‐CoV‐2
anti‐CCP
Language English
License Attribution
2024 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.
This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4706-32b5942267616e6bb25c3c6b698a5744a54823becc6c345c4e6c057c4947c32d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-3516-0130
0000-0002-5421-5280
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11112627/
PMID 38780036
PQID 3061112279
PQPubID 2034588
PageCount 8
ParticipantIDs doaj_primary_oai_doaj_org_article_29444eabfa2b470eb12ae55e7de39530
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11112627
proquest_miscellaneous_3059257045
proquest_journals_3061112279
crossref_primary_10_1002_iid3_1276
pubmed_primary_38780036
wiley_primary_10_1002_iid3_1276_IID31276
PublicationCentury 2000
PublicationDate May 2024
PublicationDateYYYYMMDD 2024-05-01
PublicationDate_xml – month: 05
  year: 2024
  text: May 2024
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Bognor Regis
– name: Hoboken
PublicationTitle Immunity, Inflammation and Disease
PublicationTitleAlternate Immun Inflamm Dis
PublicationYear 2024
Publisher John Wiley & Sons, Inc
John Wiley and Sons Inc
Wiley
Publisher_xml – name: John Wiley & Sons, Inc
– name: John Wiley and Sons Inc
– name: Wiley
References 2023; 10
2021; 4
2013; 28
2023; 56
2020; 382
2017; 69
2019; 105
2016; 75
2024; 142
2020; 13
2020; 12
2023; 329
2021; 122
2022; 44
2018; 20
2022; 611
2023; 61
2023; 42
2023; 21
2018; 9
2020; 6
2004; 50
2021; 98
2022; 185
2021; 12
2021; 34
2006; 65
2009; 72
2020; 395
2020; 72
2021; 131
2022; 32
2021; 595
2020; 22
2007; 3
2022; 33
2022; 11
2024; 25
2021; 41
2024; 27
2012; 64
2021; 80
e_1_2_11_10_1
e_1_2_11_32_1
e_1_2_11_31_1
e_1_2_11_30_1
e_1_2_11_36_1
e_1_2_11_14_1
e_1_2_11_13_1
e_1_2_11_35_1
e_1_2_11_12_1
e_1_2_11_34_1
e_1_2_11_11_1
e_1_2_11_33_1
e_1_2_11_7_1
e_1_2_11_29_1
e_1_2_11_6_1
e_1_2_11_28_1
e_1_2_11_5_1
Son K (e_1_2_11_21_1) 2023; 61
e_1_2_11_27_1
e_1_2_11_4_1
e_1_2_11_26_1
e_1_2_11_3_1
e_1_2_11_2_1
e_1_2_11_44_1
e_1_2_11_20_1
e_1_2_11_45_1
e_1_2_11_25_1
e_1_2_11_40_1
e_1_2_11_24_1
e_1_2_11_41_1
e_1_2_11_9_1
e_1_2_11_23_1
e_1_2_11_42_1
e_1_2_11_8_1
e_1_2_11_22_1
e_1_2_11_43_1
e_1_2_11_18_1
e_1_2_11_17_1
e_1_2_11_16_1
e_1_2_11_15_1
e_1_2_11_37_1
e_1_2_11_38_1
e_1_2_11_39_1
e_1_2_11_19_1
References_xml – volume: 20
  start-page: 264
  issue: 1
  year: 2018
  article-title: The presence of anti‐nuclear antibodies alone is associated with changes in B cell activation and T follicular helper cells similar to those in systemic autoimmune rheumatic disease
  publication-title: Arthritis Res Ther
– volume: 122
  year: 2021
  article-title: Unique autoantibody prevalence in long‐term recovered SARS‐CoV‐2‐infected individuals
  publication-title: J Autoimmun
– volume: 33
  issue: 2
  year: 2022
  article-title: Partners in crime: autoantibodies complicit in COVID‐19 pathogenesis
  publication-title: Rev Med Virol
– volume: 142
  year: 2024
  article-title: Novel and unique rheumatoid factors cross‐react with viral epitopes in COVID‐19
  publication-title: J Autoimmun
– volume: 75
  start-page: 1866
  issue: 10
  year: 2016
  end-page: 1875
  article-title: Single cell cloning and recombinant monoclonal antibodies generation from RA synovial B cells reveal frequent targeting of citrullinated histones of NETs
  publication-title: Ann Rheum Dis
– volume: 42
  start-page: 2905
  issue: 10
  year: 2023
  end-page: 2914
  article-title: Incident autoimmune diseases in association with SARS‐CoV‐2 infection: a matched cohort study
  publication-title: Clin Rheumatol
– volume: 185
  start-page: 881
  issue: 5
  year: 2022
  end-page: 895.e20e820
  article-title: Multiple early factors anticipate post‐acute COVID‐19 sequelae
  publication-title: Cell
– volume: 25
  start-page: 48
  issue: 1
  year: 2024
  article-title: What is the actual relationship between neutrophil extracellular traps and COVID‐19 severity? A longitudinal study
  publication-title: Respir Res
– volume: 4
  year: 2021
  article-title: Latent rheumatic, thyroid and phospholipid autoimmunity in hospitalized patients with COVID‐19
  publication-title: J Transl Autoimmun
– volume: 12
  issue: 570
  year: 2020
  article-title: Prothrombotic autoantibodies in serum from patients hospitalized with COVID‐19
  publication-title: Sci Transl Med
– volume: 21
  start-page: 2569
  issue: 9
  year: 2023
  end-page: 2584
  article-title: NETosis induction reflects COVID‐19 severity and long COVID: insights from a 2‐center patient cohort study in Israel
  publication-title: J Thromb Haemost
– volume: 105
  year: 2019
  article-title: Cellular aging over 13 years associated with incident antinuclear antibody positivity in the Baltimore longitudinal study of aging
  publication-title: J Autoimmun
– volume: 32
  issue: 4
  year: 2022
  article-title: Complement inhibition: a possible therapeutic approach in the fight against Covid‐19
  publication-title: Rev Med Virol
– volume: 41
  start-page: 1523
  issue: 8
  year: 2021
  end-page: 1529
  article-title: ANCA‐associated vasculitis after COVID‐19
  publication-title: Rheumatol Int
– volume: 72
  start-page: 732
  issue: 6
  year: 2009
  end-page: 735
  article-title: Porphyromonas gingivalis may play an important role in the pathogenesis of periodontitis‐associated rheumatoid arthritis
  publication-title: Med Hypotheses
– volume: 56
  year: 2023
  article-title: Risk of autoimmune diseases in patients with COVID‐19: a retrospective cohort study
  publication-title: EClinicalMedicine
– volume: 69
  start-page: 1165
  issue: 6
  year: 2017
  end-page: 1175
  article-title: Anti‐citrullinated protein antibodies are associated with neutrophil extracellular traps in the sputum in relatives of rheumatoid arthritis patients
  publication-title: Arthritis Rheumatol
– volume: 22
  start-page: 27
  issue: 1
  year: 2020
  article-title: Association between periodontitis and anti‐citrullinated protein antibodies in rheumatoid arthritis patients: a cross‐sectional study
  publication-title: Arthritis Res Ther
– volume: 3
  start-page: 721
  issue: 5
  year: 2007
  end-page: 738
  article-title: Clinical implication of autoantibodies in patients with systemic rheumatic diseases
  publication-title: Expert Rev Clin Immunol
– volume: 329
  start-page: 701
  year: 2023
  article-title: Long COVID linked with unemployment in new analysis
  publication-title: JAMA
– volume: 6
  start-page: 71
  issue: 1
  year: 2020
  article-title: ANCA‐associated vasculitis
  publication-title: Nat Rev Dis Primers
– volume: 72
  start-page: 1998
  issue: 12
  year: 2020
  end-page: 2004
  article-title: Antiphospholipid antibodies in critically ill patients with COVID‐19
  publication-title: Arthritis Rheumatol
– volume: 27
  year: 2024
  article-title: Association of vascular netosis with COVID‐19 severity in asymptomatic and symptomatic patients
  publication-title: iScience
– volume: 12
  start-page: 5417
  issue: 1
  year: 2021
  article-title: New‐onset IgG autoantibodies in hospitalized patients with COVID‐19
  publication-title: Nat Commun
– volume: 9
  year: 2018
  article-title: Autoantibodies in autoimmune liver disease‐clinical and diagnostic relevance
  publication-title: Front Immunol
– volume: 611
  start-page: 139
  issue: 7934
  year: 2022
  end-page: 147
  article-title: Dysregulated naive B cells and de novo autoreactivity in severe COVID‐19
  publication-title: Nature
– volume: 4
  issue: 11
  year: 2021
  article-title: Autoimmune anti‐DNA and anti‐phosphatidylserine antibodies predict development of severe COVID‐19
  publication-title: Life Sci Alliance
– volume: 395
  start-page: 497
  issue: 10223
  year: 2020
  end-page: 506
  article-title: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
  publication-title: Lancet
– volume: 44
  start-page: 145
  issue: 2
  year: 2022
  end-page: 149
  article-title: Systemic lupus erythematosus after coronavirus disease‐2019 (COVID‐19) infection: case‐based review
  publication-title: Egypt Rheumatol
– volume: 61
  issue: 1
  year: 2023
  article-title: Circulating anti‐nuclear autoantibodies in COVID‐19 survivors predict long COVID symptoms
  publication-title: Eur Respir J
– volume: 50
  start-page: 380
  issue: 2
  year: 2004
  end-page: 386
  article-title: Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors
  publication-title: Arthritis Rheum
– volume: 382
  start-page: 1708
  issue: 18
  year: 2020
  end-page: 1720
  article-title: Clinical characteristics of coronavirus disease 2019 in China
  publication-title: N Engl J Med
– volume: 28
  start-page: 25
  issue: 1
  year: 2013
  end-page: 28
  article-title: Anti‐citrullinated protein antibodies in rheumatoid arthritis: a bridge between genetic predisposition and autoimmunity
  publication-title: Korean J Intern Med
– volume: 595
  start-page: 283
  issue: 7866
  year: 2021
  end-page: 288
  article-title: Diverse functional autoantibodies in patients with COVID‐19
  publication-title: Nature
– volume: 11
  start-page: 2901
  issue: 18
  year: 2022
  article-title: Dysregulated neutrophil phenotype and function in hospitalised non‐ICU COVID‐19 pneumonia
  publication-title: Cells
– volume: 65
  start-page: 366
  issue: 3
  year: 2006
  end-page: 371
  article-title: Smoking is a risk factor for anti‐CCP antibodies only in rheumatoid arthritis patients who carry HLA‐DRB1 shared epitope alleles
  publication-title: Ann Rheum Dis
– volume: 80
  start-page: 1096
  issue: 8
  year: 2021
  end-page: 1098
  article-title: Onset of rheumatoid arthritis after COVID‐19: coincidence or connected?
  publication-title: Ann Rheum Dis
– volume: 64
  start-page: 2319
  issue: 7
  year: 2012
  end-page: 2327
  article-title: Prevalence and sociodemographic correlates of antinuclear antibodies in the United States
  publication-title: Arthritis Rheum
– volume: 131
  issue: 24
  year: 2021
  article-title: The intersection of COVID‐19 and autoimmunity
  publication-title: J Clin Invest
– volume: 34
  issue: 1
  year: 2021
  article-title: Cell‐type‐specific immune dysregulation in severely ill COVID‐19 patients
  publication-title: Cell Rep
– volume: 10
  year: 2023
  article-title: Brief report: can COVID‐19 infection trigger rheumatoid arthritis‐associated autoimmunity in individuals at risk for the disease? A nested cohort study
  publication-title: Front Med
– volume: 98
  year: 2021
  article-title: Advanced glycation end products (AGEs) and its receptor, RAGE, modulate age‐dependent COVID‐19 morbidity and mortality. A review and hypothesis
  publication-title: Int Immunopharmacol
– volume: 13
  start-page: 1077
  issue: 6
  year: 2020
  end-page: 1086
  article-title: Clinical and autoimmune characteristics of severe and critical cases of COVID‐19
  publication-title: Clin Transl Sci
– ident: e_1_2_11_8_1
  doi: 10.1038/s41586-022-05273-0
– ident: e_1_2_11_35_1
  doi: 10.1186/s13075-020-2121-6
– ident: e_1_2_11_9_1
  doi: 10.1016/j.jtauto.2021.100091
– ident: e_1_2_11_7_1
  doi: 10.1002/rmv.2316
– ident: e_1_2_11_31_1
  doi: 10.1002/art.41425
– ident: e_1_2_11_36_1
  doi: 10.1016/j.mehy.2008.12.040
– ident: e_1_2_11_14_1
  doi: 10.1016/j.jaut.2023.103132
– ident: e_1_2_11_18_1
  doi: 10.1111/cts.12805
– ident: e_1_2_11_26_1
  doi: 10.26508/lsa.202101180
– ident: e_1_2_11_39_1
  doi: 10.1007/s10067-023-06670-0
– ident: e_1_2_11_4_1
  doi: 10.1002/rmv.2412
– ident: e_1_2_11_32_1
  doi: 10.1016/j.jaut.2021.102682
– ident: e_1_2_11_43_1
  doi: 10.1186/s12931-023-02650-9
– ident: e_1_2_11_12_1
  doi: 10.1126/scitranslmed.abd3876
– ident: e_1_2_11_2_1
  doi: 10.1586/1744666X.3.5.721
– ident: e_1_2_11_37_1
  doi: 10.1136/annrheumdis-2021-219859
– ident: e_1_2_11_15_1
  doi: 10.1002/art.20018
– ident: e_1_2_11_29_1
  doi: 10.1007/s00296-021-04914-3
– volume: 61
  issue: 1
  year: 2023
  ident: e_1_2_11_21_1
  article-title: Circulating anti‐nuclear autoantibodies in COVID‐19 survivors predict long COVID symptoms
  publication-title: Eur Respir J
  contributor:
    fullname: Son K
– ident: e_1_2_11_40_1
  doi: 10.3389/fmed.2023.1201425
– ident: e_1_2_11_11_1
  doi: 10.1038/s41586-021-03631-y
– ident: e_1_2_11_42_1
  doi: 10.1136/annrheumdis-2015-208356
– ident: e_1_2_11_13_1
  doi: 10.1016/j.cell.2022.01.014
– ident: e_1_2_11_5_1
  doi: 10.1016/S0140-6736(20)30183-5
– ident: e_1_2_11_28_1
  doi: 10.1038/s41572-020-0204-y
– ident: e_1_2_11_17_1
  doi: 10.3389/fimmu.2018.00609
– ident: e_1_2_11_22_1
  doi: 10.1016/j.intimp.2021.107806
– ident: e_1_2_11_25_1
  doi: 10.1002/art.34380
– ident: e_1_2_11_10_1
  doi: 10.1038/s41467-021-25509-3
– ident: e_1_2_11_23_1
  doi: 10.1016/j.jaut.2019.06.006
– ident: e_1_2_11_34_1
  doi: 10.3904/kjim.2013.28.1.25
– ident: e_1_2_11_38_1
  doi: 10.1016/j.eclinm.2022.101783
– ident: e_1_2_11_45_1
  doi: 10.1016/j.isci.2024.109573
– ident: e_1_2_11_20_1
  doi: 10.1001/jama.2023.0157
– ident: e_1_2_11_24_1
  doi: 10.1016/j.celrep.2020.108590
– ident: e_1_2_11_33_1
  doi: 10.1136/ard.2005.041079
– ident: e_1_2_11_41_1
  doi: 10.1002/art.40066
– ident: e_1_2_11_19_1
  doi: 10.1172/JCI154886
– ident: e_1_2_11_16_1
  doi: 10.1186/s13075-018-1752-3
– ident: e_1_2_11_30_1
  doi: 10.3390/cells11182901
– ident: e_1_2_11_3_1
  doi: 10.1002/art.20018
– ident: e_1_2_11_27_1
  doi: 10.1016/j.ejr.2021.08.013
– ident: e_1_2_11_6_1
  doi: 10.1056/NEJMoa2002032
– ident: e_1_2_11_44_1
  doi: 10.1016/j.jtha.2023.02.033
SSID ssj0001037308
Score 2.3084266
Snippet Objectives The dysregulated immune response is one of the cardinal features of severe coronavirus disease 2019 (COVID‐19). This study was conducted to clarify...
The dysregulated immune response is one of the cardinal features of severe coronavirus disease 2019 (COVID-19). This study was conducted to clarify the...
Abstract Objectives The dysregulated immune response is one of the cardinal features of severe coronavirus disease 2019 (COVID‐19). This study was conducted to...
ObjectivesThe dysregulated immune response is one of the cardinal features of severe coronavirus disease 2019 (COVID-19). This study was conducted to clarify...
Abstract Objectives The dysregulated immune response is one of the cardinal features of severe coronavirus disease 2019 (COVID‐19). This study was conducted to...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
wiley
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage e1276
SubjectTerms Adult
Aged
Anti-Citrullinated Protein Antibodies - blood
Anti-Citrullinated Protein Antibodies - immunology
Antibodies
Antibodies, Antinuclear - blood
Antibodies, Antinuclear - immunology
anti‐CCP
autoantibodies (AABs)
Autoantibodies - blood
Autoantibodies - immunology
Autoimmune diseases
Autoimmune Diseases - blood
Autoimmune Diseases - immunology
autoimmunity
Coronaviruses
Correlation analysis
COVID-19
COVID-19 - blood
COVID-19 - immunology
Female
Humans
Immunoglobulins
Lupus
Male
Middle Aged
Neutrophils
Original
Patients
Peptides
Rheumatic diseases
Rheumatic Diseases - blood
Rheumatic Diseases - immunology
Rheumatoid arthritis
SARS-CoV-2 - immunology
SARS‐CoV‐2
Sea level
Severity of Illness Index
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LixQxEA6yIHgR37auEsXDemh3OqmkO0edddkRfBxc2VvIExuke_GBzM2f4G_0l1jVmRlnUPHibegUTeb7Kl2V7spXjD2aJR_AB1Gb2KoaTAO1yS7UXYBZEN6kRtMB55ev9MkpvDhTZ1utvqgmrMgDF-AOhQGA5Hx2wkOLt26ES0qlNiZplCy79UZtbaamtyszia7braWEZuKw76N80gjSFtkKQJNO_5-Sy99rJLdz1yn4HF9hl1dZI39aZnuVXUjDNXax9JFcXmcJyebxV_kPHzNHxPqwDB_6wAOdrCDtbcwrIz-nOpaY-AFZ_Pj2fT5_83iy9mNc8ox-MX7FeMYxZKaPic9fv1scoVljbrDT4-dv5yf1qn9CHRApXUvhlaGTsq1udNLeCxVk0F6bzqkWwOFuRUgiUQcJKkDSAdO3AAbaIEWUN9neMA7pNuNJZwz1jYqxM5AxqTNOq5xB5eg6HKjYwzWo9rzIZNgiiCwsIW8J-Yo9I7g3BqRsPV1Avu2Kb_svviu2vybLrpbbJ4v7HnxmkxhixR5shnGh0NcPN6TxC9koQy37QFXsVuF2MxPZtR0p81Ss22F9Z6q7I0P_fhLjppAjtGgrdjA5yN__vl0sjiT9uPM_cLjLLgnMr0rt5T7bQ0dK9zA_-uzvT0vhJzBjDvU
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Coronavirus Research Database
  dbid: COVID
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB7BVkhceFMCBRnEoRyyTfxKfEKwpeoi8ThQ1FsUPwIRKFn6EFp-PTN57HZ5HbhFsQ925hvPF3v8DcDTJFgnreOx8ZmKpUllbKrSxbmTiePWhFTTBec3b_XhkXx9rI6HDbfTIa1yXBO7hdq3jvbI95DaoluS3t3zxbeYqkbR6epQQuMybIkc_3QmsDV793G-v95lSQRCOB8lhRK-V9deTFNOGiMXAlGn1_8nkvl7ruRFDtsFoYPrUIzD73NPvkzPz-zU_fhF2fH_53cDrg38lL3oAXUTLoXmFlzpK1Yub0OJsGJ-nWjE2oqhbWq3dF9rxxzd4SCVb2Swni0oY8YHtks94tns_bOur239klWIv_Y7xk2GoTmcBNZ90Tg1d-Do4NWH2WE8VGmIncwocY5bZeg-bqZTHbS1XDnhtNUmL1UmZYn_RFwQVLQTUjkZtEOS6KSRmRPci7swadom3AMWdIWEIlXe50ZWSB1NqVVVSVX5MseGCJ6MJisWvRhH0csu84LsWpBdI3hJxlx1IP3s7kV78qkY3LHgRkoZSluV3OIsMGDxMigVMh-EUSKJYGe0UjE49WmxNlEEj1fN6I50xlI2oT2nPspQYUCpItjukbMaiciznPR_Isg3MLUx1M2Wpv7cSX5TYOOaZxHsdvD7-_SL-Xxf0MP9f0_hAVzlyM_63M0dmCA8wkPkV2f20eBEPwGWgia4
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Open Access Journals
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Nb9QwELVKERIXxHdTCjKIQzmkJPbYjg8IwZaqi1TgwKLeovgjEKlKyhYEe-Mn8Bv5Jcwk2aUrisQtiidSMvOceU7Gbxh7nEXnwXmR2mBUCjaH1NaVTwsPmRfOxlzTBuejN_pwBq-P1fEGW_bYHB14duHSjvpJzeYne98_L57jhH82Cog-bZog93Jh9CV2WYAEAvrRyPL7Ty2ZRBz3vekylaWghFlqDJ2_ei0z9QL-F7HOv4snz5PaPisdXGfXRjrJXwzxv8E2YnuTXRkaTC5usYgo4OFPXRDvao6ubPzCnzSee9pyQaLcSDgDP6UClxD5Lln8-vFzMnn3pLd2XVjwGgHTfcNExzGXxnnkk7cfpvtoltvbbHbw6v3kMB0bK6QeDNW6CacsbaE1OtdROyeUl147bYtKGYAKlzFCUnS1l6A8RO2R13mwYLwUQd5hm23Xxi3Go66RA-QqhMJCjWzPVlrVNag6VAUOJOzR0qnl6aCfUQ5KyaIkz5fk-YS9JHevDEjyuj_RzT-W4wwqhQWAWLm6Eg6fAnOMqKJS0YQorZJZwnaWwSqXMCpxQYQvc1JJTNjD1TDOIPotUrWx-0o2ylIvP1AJuzvEdnUnsjAFSfYkrFiL-tqtro-0zadepZtykdDCJGy3B8i_H7-cTvclHWz_v-k9dlUgvRpKL3fYJsIl3kd69MU96MH_GwbqDJI
  priority: 102
  providerName: Scholars Portal
– databaseName: Open Access: Wiley-Blackwell Open Access Journals
  dbid: 24P
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwEB6VIiQuiDeBggziUA6hiZ-xOMGWqosE9EBRb5FfKZFQUrUgtDd-Ar-RX8JMsptlBUjcongi2fPwfHbGnwGeFskH6QPPbTQql7aUuW1cyKsgi8C9TaWmA85v3-nDY_nmRJ1swYvVWZiRH2LacKPIGOZrCnDnL_bWpKFtG8Xzkht9CS4jrKnIpbk8Wm-wFAK9d7iRrlBFLhU3K2ahgu9NX2_ko4G2_29Y88-Syd-h7JCLDq7DtSWIZC9Hq9-ArdTdhCvjtZKLW5DQ9iyuq4FY3zBUYBsW4XMbWKCDFkTFjTAzsjMqa4mJ7ZLEz-8_ZrOjZ4O07-OCNegm_TdMbwwzaDpPbPb-43wfxUp7G44PXn-YHebL6xTyIA1VuHGvLB2cNbrUSXvPVRBBe20rp4yUDhcvXJBNdRBSBZl0QDQXpJUmCB7FHdju-i7dA5Z0g5m_VDFWVjaI8azTqmmkaqKrsCGDJyul1mcja0Y98iPzmjRfk-YzeEXqngSI6Hp40Z-f1su4qbmVUibnG8c9jgIzC3dJqWRiElaJIoOdlbHqZfRd1LgMwimcuBEzeDw1Y9zQzxDXpf4ryShLN_hJlcHd0bZTT0RlKiLqyaDasPpGVzdbuvbTwM1NGYhrbjLYHRzk38Ov5_N9QQ_3_1_0AVzlCKrGgssd2EZ3SQ8RFH3xjwbn_wU8kAfj
  priority: 102
  providerName: Wiley-Blackwell
Title The development of anticyclic citrullinated peptide (anti‐CCP) antibody following severe COVID‐19
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fiid3.1276
https://www.ncbi.nlm.nih.gov/pubmed/38780036
https://www.proquest.com/docview/3061112279
https://www.proquest.com/docview/3059257045/abstract/
https://pubmed.ncbi.nlm.nih.gov/PMC11112627
https://doaj.org/article/29444eabfa2b470eb12ae55e7de39530
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEB41RUhcEG8MJVoQh3JwYu_Te6RpqwYpJUIU5WZ512uw1NpRAaHc-An8Rn4Js-s4JAIuXGzLO5J356GZWc98C_AyccZyY2msSyVirlMe66qwcWZ5YqnRLpW-wXl2Ls8u-JuFWOyB7HthQtG-NfWoubwaNfWnUFu5vLLjvk5sPJ9NvJlTiUn7AAaKsa0cPeysJAzVNuthhBI6ruuSjVLqcUW2nE_A6P9bYPlnfeR23Bocz-kduL2OGMnrbmZ3Yc819-Bmd4bk6j44FDQpf5f-kLYiyK3aruxlbYn1XRUedxtjypIsfQ1L6cihp_j5_cdkMn8VqE1brkiFOtF-Q19G0F26a0cmbz9Mj5Es1Q_g4vTk_eQsXp-dEFuufDkbNUL7LlklU-mkMVRYZqWROiuE4rzATIUyL0BpGReWO2kxdLNcc2UZLdlD2G_axj0G4mSFbj4VZZlpXmFApwspqoqLqiwyHIjgRc_UfNlBZOQdGDLNPedzz_kIjjy7NwQe1Tq8aK8_5mvZ5lRzzl1hqoIaXAW6EVo4IZwqHdOCJREc9MLK16b2Ocecx6sDVTqC55thNBL_56NoXPvV0wjtj-vjIoJHnWw3M2GZyjwqTwTZjtR3pro7gnoZgLh7PYzgMCjIv5efT6fHzD88-f-vPIVbFCOqrtryAPZRfdwzjIi-mCEMKJ_jVS3UEG4cnZzP3-E9KMkw7DLgdcazYTCUXxhKFGE
link.rule.ids 230,315,733,786,790,870,891,2115,2236,11589,12083,21416,24346,27955,27956,31752,31753,33777,33778,38549,43343,43838,43928,46085,46509,50847,50956,53825,53827,74100,74657,74767
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB7BVgguvAuBAgZxKIdsN34lPiHYUu1CWzi0qDcrfgRWoM3Sh9Dy65lJsrstrwO3KPbBznzj-WKPvwF4PojOS-d5akKuUmkymZqq9Gnh5cBzZ2Km6YLz3r4eHcq3R-qo23A76dIqF2tis1CH2tMe-RZSW3RL0rt7OfuWUtUoOl3tSmhchjUMrLzowdrw_cfx9mqXZSAQwsVCUmjAtyaTIPoZJ42Rc4Go0ev_E8n8PVfyPIdtgtDODbCL4be5J1_6Z6eu73_8ouz4__O7Cdc7fspetYC6BZfi9DZcaStWzu9AibBiYZVoxOqKoW0mfu6_TjzzdIeDVL6RwQY2o4yZENkm9UiHww8vmr6uDnNWIf7q7xg3GYbmeBxZ80XTzNyFw503B8NR2lVpSL3MKXGOO2XoPm6uMx21c1x54bXTpihVLmWJ_0RcEFS0F1J5GbVHkuilkbkXPIh16E3rabwPLOoKCUWmQiiMrJA6mlKrqpKqCmWBDQk8W5jMzloxDtvKLnNLdrVk1wRekzGXHUg_u3lRH3-ynTtabqSUsXRVyR3OAgMWL6NSMQ9RGCUGCWwsrGQ7pz6xKxMl8HTZjO5IZyzlNNZn1EcZKgwoVQL3WuQsRyKKvCD9nwSKC5i6MNSLLdPJ50bymwIb1zxPYLOB39-nb8fjbUEPD_49hSdwdXSwt2t3x_vvHsI1jlytzePcgB5CJT5CrnXqHncO9RN8pymf
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwELZgEYgL4k1gAYM4LIfQxM_4hKCl2vJY9sCi3iy_ApFQU3ZBqP-emSRtt-Jxi-I52PPwfInH3xDyrEg-CB9YbqKWuTClyE3tQl4FUQTmTSoVXnD-cKQOT8TbuZwP9U9nQ1nlek_sNurYBvxHPgJoC2GJfHejeiiLOJ5MXy6_59hBCk9ah3YaF8klyJIFtnHQc73931JwcOZqTS5UsFHTRP6iZMg2ci4ldcz9f4Obf1ZNnkezXTqaXifXBhxJX_WGv0EupMVNcrnvLLm6RRyYn8ZtQRBtawo6bMIqfGsCDXjXAtm4AWlGusTKlpjoAUrk4_Hx807Wt3FFa_CT9hfkNwopNJ0mOv74eTbJS3ObnEzffBof5kM3hTwIjQVuzEuD92a1KlVS3jMZeFBemcpJLYSDbxfG0aQqcCGDSCoAmAvCCB04i_wO2Vu0i3SP0KRqSPyljLEyogaIZ5ySdS1kHV0FAxl5ulaoXfakGbanR2YWtW5R6xl5jareCCDPdfeiPf1ih7CxzAghkvO1Yx5WAYmFuSRl0jFxI3mRkf21oewQfGd26yoZebIZhrDBsxC3SO1PlJEGG_gJmZG7vV03M-GVrpCnJyPVjsV3pro7smi-dtTcmICYYjojB51z_Hv5djabcHy4__8lPCZXwM_t-9nRuwfkKgNI1Zdb7pM98JT0ECDRD_-o8_XfVFIJhA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+development+of+anticyclic+citrullinated+peptide+%28anti%E2%80%90CCP%29+antibody+following+severe+COVID%E2%80%9019&rft.jtitle=Immunity%2C+Inflammation+and+Disease&rft.au=Roghani%2C+Seyed+Askar&rft.au=Dastbaz%2C+Mohammad&rft.au=Lotfi%2C+Ramin&rft.au=Shamsi%2C+Afsaneh&rft.date=2024-05-01&rft.issn=2050-4527&rft.eissn=2050-4527&rft.volume=12&rft.issue=5&rft.epage=n%2Fa&rft_id=info:doi/10.1002%2Fiid3.1276&rft.externalDBID=10.1002%252Fiid3.1276&rft.externalDocID=IID31276
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2050-4527&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2050-4527&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2050-4527&client=summon